| metric | OpenAI | Perplexity | Gemini |
|---|---|---|---|
| format | prose | prose | prose |
| word count | 1,353 | 7,170 | 2,629 |
| sources | 42 | 60 | 0 |
| processing time | 569s | 154s | 1s |
| has images | no | no | no |
| has tables | no | no | no |
| citation style | — | — | — |
The landscape of geroscience has shifted from preclinical speculation to rigorous human clinical validation. As of late 2024 and through 2025, the field has witnessed pivotal data readouts concerning four major classes of geroprotectors: mTOR inhibitors (rapamycin), biguanides (metformin), NAD+ precursors, and senolytics.
Key findings include:
The hypothesis that aging is a malleable biological process rather than an inevitable decline is now being tested in human subjects. The transition from model organisms (yeast, worms, mice) to humans introduces significant complexity, particularly regarding dosage, safety profiles in non-diseased populations, and the selection of biomarkers. Current clinical trials focus less on "lifespan" (which takes decades to measure) and more on "healthspan" metrics, including epigenetic clocks, frailty indices, cognitive function, and mitochondrial competency.
This report synthesizes data from 2024 and 2025 to evaluate the efficacy and safety of the most prominent anti-aging interventions.
Rapamycin (Sirolimus), an FDA-approved immunosuppressant, acts by inhibiting the mechanistic target of rapamycin (mTOR), specifically the mTORC1 complex, which regulates cell growth and autophagy. It is currently considered the "gold standard" for pharmacological lifespan extension in animal models.
The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial, a randomized, double-blind, placebo-controlled study, released its findings in April 2025. This study aimed to assess the safety and efficacy of intermittent (weekly) low-dose rapamycin in healthy older adults [cite: 1, 2].
A comprehensive meta-analysis published in Aging Cell (June 2025) analyzed 167 studies across eight vertebrate species to compare the lifespan-extending effects of Rapamycin, Metformin, and Dietary Restriction (DR) [cite: 5, 6].
The PEARL trial suggests that rapamycin's utility in humans may lie in preserving functional capacity (muscle mass) rather than simply reducing fat. The specific targeting of mTORC1 appears to induce autophagy without the deleterious side effects associated with continuous high-dose inhibition (which affects mTORC2 and insulin sensitivity) [cite: 1]. Future trials are expected to explore higher doses and longer durations to establish definitive longevity benefits [cite: 2].
Metformin, a first-line treatment for Type 2 diabetes, acts primarily by activating AMPK and inhibiting Complex I of the mitochondrial electron transport chain. It has been hypothesized to act as a "caloric restriction mimetic."
The Targeting Aging with Metformin (TAME) trial, led by Dr. Nir Barzilai, was designed to test whether metformin can delay the onset of a composite of age-related diseases (cancer, cardiovascular disease, dementia) in non-diabetics.
Despite the delays in TAME, a groundbreaking study published in Cell (2024) provided robust evidence for metformin's neuroprotective effects in primates [cite: 9, 10, 11].
While the 2025 meta-analysis suggests rapamycin is superior for lifespan extension [cite: 6, 14], metformin appears to have a distinct and potent role in specific organ protection, particularly the brain and liver. The divergence suggests that rapamycin may be a "generalist" longevity drug, while metformin may be a "specialist" for metabolic and neuro-cognitive preservation [cite: 15]. Furthermore, metformin's safety profile is established over 60 years of human use, whereas rapamycin's off-label safety is only recently being validated [cite: 14].
Nicotinamide Adenine Dinucleotide (NAD+) declines with age, compromising mitochondrial function and DNA repair. Supplementation with precursors like Nicotinamide Riboside (NR) and Nicotinamide Mononucleotide (NMN) aims to restore these levels.
A critical human trial published in Nature Metabolism (2025) directly compared the pharmacokinetics of NR, NMN, and Nicotinamide (Nam) in healthy adults [cite: 16].
A 2025 clinical trial conducted by Chiba University provided the first evidence of NR's efficacy in Werner Syndrome, a genetic premature aging disorder [cite: 17, 18].
A 2024 randomized controlled trial evaluated NMN (250 mg/day) in older adults over 12 weeks [cite: 21].
Senolytics are compounds designed to induce apoptosis specifically in senescent ("zombie") cells that accumulate with age and secrete inflammatory factors (SASP). The most studied combination is Dasatinib (a tyrosine kinase inhibitor) and Quercetin (a flavonoid).
A longitudinal study examining the effects of Dasatinib and Quercetin (D+Q) revealed a complex biological response [cite: 25, 26].
Beyond the four primary categories, two interventions have made significant strides in 2024/2025.
Urolithin A is a postbiotic metabolite that activates mitophagy (recycling of defective mitochondria).
Partial epigenetic reprogramming involves using Yamanaka factors (OSK) to reset the epigenome of cells to a youthful state without inducing pluripotency (which risks cancer).
| Intervention | Mechanism | Key 2024/2025 Human Finding | Primary Benefit Observed | Status |
|---|---|---|---|---|
| Rapamycin | mTORC1 Inhibition | PEARL Trial: Safe in healthy adults; increased lean mass in women [cite: 2]. | Muscle preservation, pain reduction. | Phase 2/3 (Off-label studies) |
| Metformin | AMPK Activation | Primate Study: 6-year brain age reduction [cite: 10]. Vertebrate meta-analysis: No lifespan extension [cite: 6]. | Neuroprotection, metabolic health. | TAME pending; widely used off-label. |
| NAD+ (NR/NMN) | NAD+ Restoration | NMN/NR double blood NAD+ via gut conversion [cite: 16]. NR treats Werner syndrome symptoms [cite: 17]. | Vascular health, walking speed, sleep. | Various Phase 2 trials completed. |
| Senolytics | Senescent Cell Clearance | D+Q increases epigenetic age temporarily; Fisetin mitigates this [cite: 25]. | Clearance of senescent cells (proven), cognitive hints. | Early Phase 1/2; safety established. |
| Urolithin A | Mitophagy Induction | MitoImmune Trial: Rejuvenates T-cells and restores immune function [cite: 34]. | Immune health, muscle strength/endurance. | Multiple successful trials; commercialized. |
The years 2024 and 2025 mark a maturation point for anti-aging clinical trials. Rapamycin has solidified its position as the most robust lifespan extender in vertebrates, with human data now supporting its safety and ability to preserve muscle mass. Metformin, while struggling to prove lifespan extension in non-diabetics, has demonstrated profound neuroprotective capabilities in primates, suggesting it may be an essential "healthspan" tool for cognitive aging.
NAD+ precursors have moved beyond bioavailability debates, with clear evidence that both NMN and NR are effective at raising NAD+ through microbiome-dependent pathways, translating to tangible vascular and functional benefits. Senolytics remain promising but complex, requiring careful management of the inflammatory response associated with cell clearance.
Finally, the entry of epigenetic reprogramming into FDA-cleared human trials in 2026 represents the transition of longevity science from slowing decline to actively reversing cellular age. The most promising intervention appears to depend on the specific outcome desired: Rapamycin for general longevity and frailty prevention, Metformin for cognitive/metabolic protection, Urolithin A for mitochondrial/immune vigor, and NAD+ precursors for vascular/energy support.
Sources:
Researchers have targeted several existing drugs and compounds for “anti‐aging” effects. Four leading approaches in human trials are rapamycin (mTOR inhibitors), metformin, NAD⁺ precursors (e.g. nicotinamide riboside (NR) or NMN), and senolytics. All show promise in animal models, but human data are preliminary and mixed. Below we summarize each approach, its rationale, and recent trial findings.
Rapamycin and its analogs (rapalogs) inhibit the mTORC1 pathway, mimicking some effects of calorie restriction. In rodents, even late‐life rapamycin robustly extends median and maximum lifespan. In humans, rapamycin is an approved immunosuppressant, so its side‐effect profile is well known. Recent low‐dose trials suggest it may safely modulate aging‐related processes: for example, Mannick et al. gave elderly subjects 6 weeks of a low‐dose mTOR inhibitor (everolimus/RAD001) and found upregulation of antiviral immune genes and significantly fewer infections (plus improved flu‐vaccine responses) compared to placebo (pmc.ncbi.nlm.nih.gov). In another trial, topical rapamycin applied daily to aging skin (hand) for 8 months significantly reduced the senescence marker p16<sup>INK4a</sup> and increased collagen VII, with visibly younger‐looking skin on treated hands (pmc.ncbi.nlm.nih.gov). These results suggest rapamycin can enhance immune resilience and reduce cellular senescence in humans.
Key points:
Metformin is a widely used diabetes drug that activates AMPK and inhibits mTOR indirectly. In mice it modestly extends lifespan (∼4–6% increases) and markedly improves multiple health metrics (e.g. physical/cognitive performance, cataract formation, glucose tolerance) (pmc.ncbi.nlm.nih.gov). In humans, metformin’s safety is well established, and epidemiological studies hint at longevity benefits (metformin‐treated diabetics often live longer than those on other drugs).
The definitive test is the TAME trial (Targeting Aging with Metformin), a planned 6-year, placebo-controlled study in ~3000 non-diabetic older adults. TAME will give metformin (1500 mg/day) vs placebo to people 65–80 years and track the onset of major aging-related diseases (heart attack, stroke, heart failure, cancer, dementia/MCI) or death (pmc.ncbi.nlm.nih.gov). (No results are yet available.) Other smaller studies have looked at metabolic aging biomarkers, but none have shown clear prevention of aging diseases. A recent long-term observational study in Wales found that over 20 years type-2 diabetics on metformin initially lived slightly longer than matched non-diabetics, but this benefit vanished after ~5 years and ultimately diabetics still had shorter survival than non-diabetics (pmc.ncbi.nlm.nih.gov). This highlights that any anti-aging effect must compete with the underlying disease.
Key points:
NAD⁺ is a key metabolic cofactor that declines with age. Supplements like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) safely boost NAD⁺ levels in humans. Several short-term trials have shown dramatic increases in blood NAD⁺ after NR/NMN dosing. For example, a 12-week trial of NR raised whole-blood NAD⁺ several-fold (pmc.ncbi.nlm.nih.gov), and NR plus pterostilbene (NRPT) in another study raised NAD⁺ and lowered liver enzymes and blood pressure (pmc.ncbi.nlm.nih.gov). A small NMN trial (up to 500 mg in 10 men) found no severe adverse events (pmc.ncbi.nlm.nih.gov).
Despite safely increasing NAD⁺, no human trial has yet demonstrated clear anti-aging benefits. Markers of metabolism and muscle function typically did not improve. In one placebo-controlled study of NR (1–2 g daily), participants doubled their blood NAD⁺, but saw no changes in insulin sensitivity, exercise capacity, body composition, or muscle strength (pmc.ncbi.nlm.nih.gov). Some inflammatory cytokines (IL-6, TNF-α) fell modestly on NR, but overall effects on health endpoints were minimal. Thus, experts conclude that NR/NMN are safe NAD boosters but effects on aging or cellular function remain unproven (pmc.ncbi.nlm.nih.gov).
Key points:
Senolytics are drugs that selectively kill senescent cells, which accumulate with age and secrete inflammatory “SASP” factors. In mice, periodic senolytic treatment (e.g. dasatinib+quercetin or fisetin) improves many age-related conditions and extends healthy lifespan. Human trials are just beginning.
The first-in-humans trials used dasatinib + quercetin (D+Q). In a pilot open-label study, 14 patients with idiopathic pulmonary fibrosis (IPF, an age-related lung disease) took oral D+Q intermittently (3 days/week for 3 weeks). These patients had significant improvements in physical function: 6-minute walk distance, gait speed and chair-stand time all improved by clinically meaningful amounts (pmc.ncbi.nlm.nih.gov). No clear change in lung function or frailty index was seen, but the functional gains were notable. Similarly, in a trial of older adults with diabetic kidney disease, nine subjects took D (100 mg)+Q (1000 mg) daily for just 3 days. Eleven days later, biopsies showed large drops in senescence markers – p16^INK4a+ and p21^CIP1+ cells were reduced ~20–35% in fat and skin – and blood levels of SASP cytokines (IL-1α, IL-6, MMP-9, etc.) also fell (pmc.ncbi.nlm.nih.gov). This “hit-and-run” dosing dramatically cleared senescent cells from human tissues.
Key points:
Each approach has a sound rationale and some human data, but none is proven to reliably slow aging in people. Rapamycin analogs have the strongest lifespan effects in animals, and human trials show improved immunity and skin parameters (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Metformin is safe and epidemiologically linked to health benefits, and a large clinical trial (TAME) is underway (pmc.ncbi.nlm.nih.gov). NAD⁺ precursors are biologically plausible energy boosters and clearly raise NAD⁺ (pmc.ncbi.nlm.nih.gov), but have not yet translated to better metabolism or clinical outcomes. Senolytics have produced striking clearance of senescent cells and functional gains in small trials (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), but use in practice awaits more data. Ultimately, these interventions may be used alone or in combination, and larger, longer trials with clinical endpoints will be needed to judge their true “anti-aging” potential.
Sources: Published reviews and trial reports on aging interventions (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), and recent clinical studies of rapamycin, metformin, NAD⁺ boosters, and senolytics (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
The past decade has witnessed a remarkable transformation in aging research, with an increasing number of pharmacological interventions transitioning from preclinical validation to human clinical trials[1][4][31]. Among the most scientifically validated candidates are rapamycin, metformin, NAD+ precursor compounds, and senolytic drugs—each representing distinct mechanistic approaches to targeting the fundamental processes of aging. While animal models have consistently demonstrated lifespan-extending and healthspan-improving properties for these interventions, translating these findings to humans remains one of the most significant challenges in contemporary geroscience[1]. This comprehensive analysis synthesizes current evidence from clinical trials and ongoing studies to evaluate the promise, limitations, and comparative efficacy of these four major intervention classes in extending healthy human lifespan.
Before evaluating specific interventions, understanding the fundamental mechanisms by which these compounds exert their effects on aging processes is essential. Aging itself is no longer viewed as an inevitable and monolithic process but rather as a complex phenomenon driven by multiple interconnected pathways involving metabolic dysfunction, cellular senescence, mitochondrial impairment, and systemic inflammation[1][25]. The interventions discussed in this analysis target different nodes within these aging networks, suggesting that their coordinated use might provide superior benefits compared to monotherapy approaches.
The mammalian target of rapamycin, now properly designated as the mechanistic target of rapamycin (mTOR), functions as what can be understood as a master regulatory hub for cellular growth and metabolism[1][4]. This protein kinase integrates signals from growth factors, nutrient availability, and energy status to coordinate multiple downstream processes, including protein synthesis, lipid metabolism, and autophagy—the cellular process responsible for degrading damaged proteins and organelles[1]. Importantly, mTOR pathway activity becomes chronically elevated in many tissues with advancing age, correlating with a progressive decline in the clearance of cellular damage[1]. This observation has provided compelling theoretical justification for mTOR inhibition as a potential anti-aging strategy.
Metformin operates through distinct but overlapping mechanisms, primarily by activating AMP-activated protein kinase (AMPK), an evolutionarily conserved cellular energy sensor[2][5][25]. AMPK activation triggers a cascade of metabolic adjustments including improved insulin sensitivity, reduced oxidative stress, and modulation of mTORC1 activity itself[25]. Additionally, metformin inhibits complex I of the mitochondrial electron transport chain in a dose-dependent manner, potentially reducing the production of reactive oxygen species that contribute to cellular aging[36]. Beyond these metabolic effects, accumulating evidence suggests that metformin influences the microbiota composition and may directly suppress cancer cell growth through multiple pathways[5][25].
Nicotinamide adenine dinucleotide, or NAD+, represents a critical cofactor in cellular energy metabolism and serves as a substrate for multiple classes of enzymes including sirtuins, poly-ADP-ribose polymerases, and CD38/CD157 enzymes[6][27]. NAD+ levels decline substantially with age in virtually all organisms studied, and this depletion correlates with accelerated aging phenotypes and age-related diseases[3][6][23]. NAD+ precursor compounds such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) can bypass biosynthetic rate-limiting steps to restore intracellular NAD+ pools, thereby reactivating these critical enzymatic systems involved in DNA repair, stress response, and metabolic homeostasis[3][6][23].
Finally, cellular senescence emerges from recent aging research as a particularly tractable target for pharmacological intervention[8][11][26]. Senescent cells are characterized by an irreversible exit from the cell cycle, telomere dysfunction, and resistance to apoptotic cell death despite their metabolic activity[8]. These cells accumulate progressively with age and actively damage neighboring tissues through the secretion of pro-inflammatory cytokines, proteases, and other factors collectively termed the senescence-associated secretory phenotype (SASP)[8][11][26]. Senolytic drugs selectively eliminate these dysfunctional cells, while senomorphic agents suppress the deleterious SASP without necessarily inducing cell death[8].
Rapamycin, originally isolated from bacterial species found in soil samples from Easter Island, was initially developed as an immunosuppressive agent for organ transplantation[1][4]. A pivotal turning point in aging research occurred when rapamycin became the first small-molecule drug definitively shown to extend lifespan in mice regardless of the timing of administration[1][31]. The breadth and robustness of these preclinical findings across diverse mouse strains, sexes, and treatment initiation timepoints fundamentally established rapamycin as a reference standard against which other geroprotective interventions are measured[31][45].
Mechanistic studies revealed that rapamycin extends murine lifespan by approximately nine to fourteen percent when administration begins in mid-life[1][31]. Late-life administration proves even more remarkable—in studies at the National Institute of Aging's Interventions Testing Program, rapamycin initiated at the advanced age of twenty months extended lifespan by nine percent in female mice and fourteen percent in male mice[31][33]. This late-life efficacy carries profound implications for human applications, as it suggests that interventions need not begin in youth to generate meaningful benefits. Beyond lifespan extension, rapamycin administration associates with delayed onset of multiple age-related pathologies including malignancies and neurodegeneration[1][4]. In transgenic mouse models of Alzheimer's disease, rapamycin prevented memory deficits and reduced cognitive decline, providing specific evidence for neuroprotective effects[1].
The most extensive human clinical investigation of rapamycin for healthy aging is the Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial, a forty-eight-week decentralized, double-blind, randomized, placebo-controlled study conducted across multiple centers[9][12][31]. This landmark trial enrolled participants aged fifty to eighty-five with relatively good health and well-managed chronic conditions, administering placebo or low-dose rapamycin at five milligrams or ten milligrams weekly[9][12]. The trial design emphasized intermittent dosing—a critical strategic decision based on preclinical evidence suggesting that pulsatile rather than continuous mTOR inhibition may optimize the benefit-to-risk ratio[1][9].
Results from the PEARL trial demonstrated critical feasibility and safety data[9][31]. Most significantly, low-dose intermittent rapamycin proved well tolerated over one year with no significant increase in serious adverse events compared to placebo[9][31]. Beyond safety, the trial documented clinically meaningful improvements in women receiving the higher dose, with statistically significant improvements in lean tissue mass and self-reported pain[9][31]. Women receiving five milligrams weekly also showed improvements in emotional well-being and general health measures[9][31]. These findings, while modest compared to the dramatic lifespan extensions observed in mice, represent the most robust evidence to date that rapamycin can improve aspects of functional aging in healthy human populations.
A particularly notable mechanistic finding from recent research published in 2026 revealed that rapamycin exerts geroprotective effects in aging immune cells not merely through classical mTOR inhibitory mechanisms but through direct enhancement of genome stability[21]. In human T cells exposed to acute genotoxic stress, rapamycin suppressed senescence by directly reducing DNA lesional burden and improving cell survival[21]. Ex vivo analysis of aged immune cells from healthy donors revealed marked enrichment of DNA damage markers, senescence markers, and mTORC hyperactivation[21]. When older adults in a placebo-controlled experimental medicine study received low-dose rapamycin, p21—a marker of DNA damage-induced senescence—was significantly reduced in immune cells compared to placebo[21]. This discovery of genoprotection as a previously unrecognized mechanism fundamentally expands understanding of why rapamycin proves so broadly geroprotective.
Among the most compelling human evidence for rapamycin's anti-aging effects comes from studies demonstrating its capacity to reverse age-related immune decline[1][4][51]. In a pivotal study by Mannick and colleagues, healthy elderly individuals aged sixty-five and older receiving low-dose RAD001—a rapamycin analog—showed significantly enhanced response to influenza vaccination compared to placebo[51]. The low-dose groups receiving either 0.5 milligrams daily or 5 milligrams weekly met the study's primary endpoint, showing increased antibody titers against influenza virus strains[51]. Remarkably, the high-dose group at 20 milligrams weekly did not achieve this benefit, supporting the counterintuitive principle that optimal mTOR inhibition for immune reconstitution occurs at sub-immunosuppressive doses[51].
Mechanistically, the immune enhancement appeared to involve reduction of exhausted T cells marked by programmed death-1 expression[51]. Elderly volunteers treated with RAD001 showed lower frequencies of PD-1-positive T cells, suggesting a rejuvenation of the immune repertoire toward a more youthful profile[51]. Additional evidence supports rapamycin's capacity to reduce laboratory-confirmed respiratory tract infections in older adults receiving the mTOR inhibitor RTB101 at ten milligrams daily[51]. These findings collectively establish that rapamycin can functionally reverse key aspects of immunosenescence—the age-associated decline in immune competence—which itself represents a major driver of increased infection susceptibility and mortality in aging populations.
Despite these promising findings, significant questions remain regarding rapamycin's translation to widespread use in healthy aging populations[1][4][9]. Most critically, the modest changes observed in human biomarkers of biological aging contrast sharply with the robust lifespan extension documented in mice[1]. The PEARL trial, while demonstrating safety and some functional improvements, showed only modest changes in biological aging biomarkers over the one-year study duration[9]. This discrepancy raises the fundamental question of whether effects observed in rodent studies will translate to meaningful clinical benefits in human longevity trials[1].
Furthermore, chronic rapamycin use at higher doses generates well-documented adverse effects including mucosal ulcers, impaired wound healing, delayed tissue repair, hyperlipidemia, glucose intolerance, and increased susceptibility to infections[1][4][40]. While low-dose intermittent regimens appear substantially better tolerated, concerns persist regarding long-term immunosuppression even at these reduced exposures[1][40]. The ethical implications of exposing otherwise healthy individuals to chronic immunosuppression, however mild, remain subject to legitimate debate[1][40]. Additionally, drug-drug interactions mediated through cytochrome P450 metabolism present practical challenges to widespread use, particularly concerning interactions with common supplements and medications[1][40].
A cautionary case emerged when entrepreneur Bryan Johnson, who had publicly championed biohacking approaches including rapamycin use, subsequently discontinued the drug and expressed regret over experienced side effects including elevated blood glucose, infection susceptibility, and impaired healing[40]. This high-profile example illustrates the gap between theoretical promise and practical tolerability for even highly motivated individuals willing to accept substantial monitoring burdens[40].
Metformin's story in aging research differs fundamentally from rapamycin's trajectory[5][25][28]. Unlike rapamycin, which required investigation for anti-aging properties after immunosuppressive applications, metformin emerged as a longevity candidate from unexpected epidemiological observations. Multiple studies documented that diabetic patients receiving metformin manifest lower all-cause mortality compared not only to diabetics receiving alternative diabetes medications but even compared to non-diabetic controls[5][25]. The landmark United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that metformin reduced cardiovascular events compared with other diabetes medications and other cardiovascular risk factors[5][25]. Additional observational studies associated metformin use with reduced cancer incidence, reduced neurodegeneration risk, and improved cardiovascular outcomes[5][25][28].
Mechanistically, metformin exhibits pleiotropic effects across multiple aging-related pathways[5][25]. Beyond its well-established role in improving insulin sensitivity and lowering blood glucose through inhibition of hepatic gluconeogenesis, metformin activates AMPK, the cellular energy sensor whose activation is associated with lifespan extension across species[2][5][25]. AMPK activation triggers improvements in mitochondrial biogenesis, reduces oxidative stress, and modulates mTORC1 activity[5][25]. Additionally, metformin may directly target mitochondrial complex I in a redox-dependent manner, potentially reducing reactive oxygen species production[25][36]. Recent molecular studies reveal that metformin's effects extend to epigenetic regulation, altering histone deacetylase activity through SIRT1 activation and broadly modulating metabolic and non-metabolic gene expression linked to aging[5][13][25].
The Metformin in Longevity Study (MILES) represents the most direct investigation of metformin's effects on aging biology in humans[2][5][25]. This double-blind, placebo-controlled crossover trial enrolled fourteen older adults with impaired glucose tolerance who received metformin at 1700 milligrams daily while undergoing muscle and adipose tissue biopsies before and after treatment[5][25]. Gene expression profiling revealed that metformin modulates metabolic and non-metabolic gene expression linked to aging, providing the first direct evidence that this drug influences aging biology at the molecular level in humans[5][25]. However, the modest sample size and short study duration limited definitive conclusions regarding clinical benefits.
Far more ambitious in scope is the Targeting Aging with Metformin (TAME) trial, a double-blind, placebo-controlled multicenter study planning to enroll three thousand individuals aged sixty-five to seventy-nine[5][16][25][28]. This pivotal trial uses a novel primary endpoint—time until first occurrence of any major aging-related morbidity including coronary heart disease, stroke, congestive heart failure, peripheral arterial disease, cancer, type 2 diabetes, cognitive impairment, and mortality[5][28]. Participants receive 1500 milligrams of metformin daily for six years with mean follow-up exceeding 3.5 years[5][25]. The TAME trial represents a paradigm shift in aging research methodology, using disease and biomarkers as surrogates of the aging process itself rather than focusing exclusively on lifespan[5][25][28].
Despite epidemiological support for metformin's benefits, preclinical evidence proves surprisingly mixed. While multiple rodent studies demonstrate lifespan extension following metformin administration, effects vary substantially with strain, sex, age of initiation, and dosing regimen[5][25]. Notably, some investigations found minimal lifespan effects when metformin was initiated late in life, contradicting the pattern observed with rapamycin[5][25]. In fruit flies and rats, metformin failed to extend lifespan despite activating AMPK[5][25]. This species-specific variability raises profound questions about translating findings across evolutionary distances.
Perhaps more significantly, emerging evidence in 2025 reveals substantial uncertainty about metformin's anti-aging potential in non-diabetic populations[13]. A comprehensive contemporary evaluation critically examining metformin's position notes that "a contemporary evaluation of this literature reveals emerging uncertainty about the anti-aging potential of Metformin" in healthy individuals[13]. This represents a striking reversal from the initial enthusiasm surrounding the drug's potential for universal anti-aging application. The uncertainty highlights that metformin's benefits in diabetic patients may derive from its anti-hyperglycemic effects and cardiovascular protection rather than from direct targeting of fundamental aging mechanisms[13][25][36].
Despite uncertainties about monotherapy, metformin increasingly appears within combination therapeutic approaches[13][48]. Evidence suggests that metformin combines synergistically with newer metabolic drugs including GLP-1 receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors[13]. A meta-analysis examining combination approaches found that the triple combination of metformin plus SGLT2 inhibitor plus GLP-1 receptor agonist resulted in significantly lower all-cause mortality compared to any agent alone[13]. This finding reflects a broader paradigm shift toward multi-pathway interventions rather than single-drug strategies[13][31][45].
Precision medicine approaches may be essential for optimizing metformin's anti-aging utility[25]. The recognition that metformin's effects likely depend on baseline metabolic status, genetic background, and specific disease context suggests that broad administration to all aging individuals may prove less effective than targeted application to specifically responsive populations[13][25]. This precision approach acknowledges that individual genetic variation, metabolic phenotype, and age-related comorbidities substantially influence whether someone will derive anti-aging benefits from metformin exposure[25].
Nicotinamide adenine dinucleotide exists as one of the most fundamental molecules in cellular bioenergetics, participating as a redox cofactor in numerous metabolic pathways essential for ATP production, biosynthetic reactions, and stress response[6][23][27]. Beyond metabolic roles, NAD+ serves as a critical substrate for multiple enzyme families whose activities decline with aging, including sirtuins, poly-ADP-ribose polymerases involved in DNA damage repair, and CD38/CD157 enzymes that mediate immune and metabolic signaling[6][27]. Systemic and tissue-specific declines in NAD+ levels with advancing age correlate with multiple hallmarks of aging including mitochondrial dysfunction, impaired stress resistance, and accumulation of DNA damage[3][6][23].
This mechanistic framework provided compelling rationale for investigating whether restoring NAD+ levels through supplementation with precursor compounds could reverse aging-related decline. Multiple preclinical investigations in mice demonstrated that NAD+ precursor supplementation improved physical activity, extended longevity modestly in some studies, restored vascular function, improved glucose metabolism, and enhanced mitochondrial health[6][19][23][27]. However, preclinical lifespan studies produced inconsistent results, with some investigations showing no lifespan extension despite improvements in functional measures[33][38]. This disconnect between healthspan benefits and lifespan extension raises important questions about which outcomes truly matter clinically.
Nicotinamide riboside emerged as the first NAD+ precursor extensively studied in human trials[6][19][38]. The pioneering randomized, double-blind, placebo-controlled crossover trial by Martens and colleagues enrolled twenty-four healthy adults aged fifty-five to seventy-nine receiving either 500 milligrams NR twice daily or placebo for six weeks[6]. Oral NR supplementation proved safe and well tolerated, increasing NAD+ levels in peripheral blood mononuclear cells by approximately sixty percent compared to placebo[6]. The compound also increased nicotinic acid adenine dinucleotide (NAAD)—a downstream product of NR utilization—by approximately sevenfold, demonstrating robust engagement of NAD+ biosynthetic pathways[6].
More recently, nicotinamide mononucleotide has emerged as a leading NAD+ precursor candidate. A randomized, double-blind, placebo-controlled trial examined healthy midlife and older adults aged fifty-five to eighty receiving NMN at doses of 300, 600, or 900 milligrams daily for sixty days[19]. Blood NAD+ concentrations increased significantly in a dose-dependent manner, with six-fold elevation at the highest dose[19]. Functionally, participants treated with 600 or 900 milligrams NMN demonstrated significantly improved six-minute walking distance compared to placebo and baseline, suggesting meaningful improvements in physical endurance[19]. Perhaps most intriguingly, biological age assessed by the Aging.Ai 3.0 calculator remained unchanged in NMN-treated groups but increased significantly in the placebo group, suggesting that NMN prevented age-related deterioration in this epigenetic biomarker[19].
Additional clinical investigations demonstrated improvements in multiple physiological domains[6]. Studies reported that NR supplementation improved blood pressure and arterial stiffness in hypertensive older adults, enhanced cardiac function in patients with heart failure with reduced ejection fraction, and improved motor function in patients with ataxia—a neurodegenerative condition[6][27]. However, the therapeutic magnitude typically remains modest, and study sample sizes remain quite small by contemporary clinical trial standards[6][38].
Recognizing gaps in understanding NAD+ precursor metabolism in humans, a novel ongoing clinical trial at Brigham and Women's Hospital employs stable isotope-labeled tracers to precisely map how orally administered NMN and nicotinamide (NAM) are absorbed, metabolized, and converted to NAD+ in different tissues[3]. This mechanistic investigation enrolls sixteen young adults aged eighteen to forty and sixteen older adults aged sixty-five or above, with half receiving NMN and half receiving NAM[3]. The study uses stable isotope tracers on days one and fourteen of supplementation to track labeled precursors into blood, muscle, urine, and stool while quantifying NAD+ turnover[3]. Particular emphasis falls on comparing young versus older adult metabolism to elucidate whether aging changes the efficiency of NAD+ restoration from precursor compounds[3].
Results from this mechanistic study carry profound implications for optimizing NAD+ precursor dosing and selection across age groups. If older adults demonstrate higher NAD+ turnover or inefficient conversion from precursors to NAD+, this would argue for higher doses or alternative precursor formulations in aging populations[3]. Conversely, if bioavailability proves similar across ages, this would support similar dosing strategies regardless of age[3].
While short-term clinical trials consistently document excellent safety profiles for NMN and NR without serious adverse events, significant uncertainties persist regarding long-term supplementation[6][38][41]. NR received Generally Recognized as Safe (GRAS) status from the FDA and received approval from Health Canada, the European Food Safety Authority, and the Australian Therapeutic Goods Administration[38][41]. However, most published human studies span only weeks to months rather than years, leaving substantial unknowns regarding potential adverse effects from chronic supplementation[6][38].
Minor side effects reported in human trials include gastrointestinal disturbances, nausea, rashes, calf cramps, fatigue, headaches, and occasionally thrombocytopenia[6][38][41]. While these generally prove transient and mild, they reflect that NAD+ precursors do trigger biological responses that may occasionally exceed normal homeostatic capacity[6][38][41]. Additionally, concerns exist about potential adverse effects on glucose metabolism at elevated doses and theoretical concerns that increasing NAD+ indiscriminately might enhance survival of senescent cells or even latent cancer cells if present[38][41]. While data do not demonstrate that NAD+ supplementation causes cancer, boosting NAD+ could theoretically maintain survival of cancer cells already present through non-NAD+-dependent mechanisms[41].
More speculatively, questions arise about whether sustained elevation of NAD+ might disrupt circadian rhythm regulation, create feedback inhibition through excess NAD+ accumulation, or trigger other hormetic effects where higher doses become counterproductive[38]. The hormesis principle—where low to moderate doses stimulate beneficial effects but high doses become inhibitory—remains poorly understood for NAD+ precursors[38]. Future long-term safety studies with larger participant cohorts will be essential before NAD+ precursor compounds could be considered routine preventive interventions for aging populations[6][38].
The recognition that cellular senescence contributes substantially to age-related pathologies emerged from observations that senescent cell accumulation correlates with aging-associated dysfunction across tissues[8][11][26]. Senescent cells exhibit irreversible cell cycle arrest triggered by telomere shortening, DNA damage, or oncogenic stress, yet paradoxically remain metabolically active[8][11][26]. These persistent cells resist apoptosis through upregulation of anti-death signaling pathways and actively damage neighboring tissues through secretion of the senescence-associated secretory phenotype consisting of pro-inflammatory cytokines, proteases, and other tissue-damaging factors[8][11][26].
Pioneering research by Kirkland, van Deursen, and colleagues at Mayo Clinic demonstrated the causal contribution of senescent cells to age-related decline[11][26]. In one seminal experiment, transplantation of senescent cells into middle-aged mice induced frailty, physical dysfunction, and premature aging accompanied by early death from diseases resembling those killing naturally aging mice[11][26]. Critically, removal of these senescent cells alleviated such effects, establishing that senescent cell burden directly contributes to age-related decline[11][26]. These findings opened a radically new therapeutic avenue: selectively targeting and eliminating senescent cells as a strategy to extend healthspan and delay age-related diseases[8][11][26].
The most extensively studied senolytic combination in humans consists of dasatinib—a tyrosine kinase inhibitor originally developed for cancer treatment—combined with quercetin, a naturally derived flavonoid[7][11][26]. A landmark open-label pilot study in 2019 enrolled fourteen volunteers with idiopathic pulmonary fibrosis, a fatal progressive lung disease characterized by excessive senescent cell accumulation[11][26]. Participants received dasatinib and quercetin over three weeks, and remarkably, treatment improved physical function, with participants demonstrating improved gait speed and other functional abilities[11][26]. This proof-of-concept provided direct evidence that senolytic therapy could improve physical function in humans with age-related disease.
Subsequently, Mayo Clinic investigators conducted a randomized, placebo-controlled confirmatory trial comparing three weeks of dasatinib plus quercetin to placebo in twelve older adults with idiopathic pulmonary fibrosis[42]. All participants completed the planned dosing regimen with excellent adherence, and while non-serious adverse events occurred more frequently in the active treatment arm—primarily fatigue, nausea, and headache consistent with known dasatinib side effects—no serious adverse events occurred related to the combination[42]. The investigators concluded that dasatinib plus quercetin represents a tolerable approach suitable for phase II trials assessing clinical efficacy[42].
In patients with diabetic kidney disease, another aging-associated condition driven partially by senescent cell accumulation, senolytic therapy similarly showed promise[11][26]. Mayo Clinic researchers found that dasatinib plus quercetin cleared senescent cells from kidney tissue and improved relevant biomarkers of renal function[11][26]. Collectively, these early clinical trials demonstrate biological efficacy—senolytic drugs do clear senescent cells in human tissues and can improve disease-relevant biomarkers[11][26].
Beyond pulmonary fibrosis and diabetic kidney disease, senolytics are now being tested in secondary progressive multiple sclerosis, a severe neurodegenerative condition in which senescent cell accumulation may contribute to disease progression[10][39]. The trial employs dasatinib and quercetin in patients aged fifty to eighty-five with documented MS progression over the preceding twelve months[10][39]. A parallel trial is investigating senolytics combined with temozolomide for glioma patients with residual disease, exploiting potential synergy between senolytic-induced senescent cell clearance and chemotherapy-induced senescence elimination[14].
Beyond pharmaceutical senolytics, investigators are exploring fisetin—a naturally occurring flavonoid from dietary sources including strawberries, onions, and cucumbers—as a potential senolytic[15][18][29]. In preclinical studies, fisetin proved more potent than quercetin at reducing senescence markers[15]. Critically, both acute and chronic treatment of old mice with fisetin reduced senescence markers across multiple tissues, with late-life fisetin administration producing sustained improvements in healthspan and even lifespan[15][18]. Treatment with fisetin reduced frailty and significantly increased grip strength—a predictor of longevity in humans—in aged mice[18]. Effects of fisetin on physical function were comparable to genetic clearance of senescent cells and to the synthetic senolytic ABT-263, suggesting that this natural compound achieves senolytic efficacy approaching pharmaceutical alternatives[15][18].
Beyond dasatinib-quercetin and fisetin, the senolytic field has expanded dramatically with diverse compounds demonstrating senolytic activity through distinct mechanisms[29]. Cardiac glycosides originally developed for heart disease treatment have been identified as senolytics capable of eliminating senescent cells in multiple tissues[8][29]. SGLT2 inhibitors—drugs used for diabetes management—unexpectedly demonstrate senolytic properties, suggesting that compounds developed for specific disease indications may have broader anti-aging applications[29][45][57]. Novel senomorphic approaches targeting the NF-κB pathway suppress senescence-associated inflammatory responses without necessarily inducing cell death, potentially offering enhanced tolerability by preserving any beneficial senescence-related functions[29].
More experimental approaches employ chimeric antigen receptor T cells (CAR-T cells) engineered to target senescence-associated antigens including NKG2D ligand and uPAR (urokinase-type plasminogen activator receptor)[29]. In naturally aged nonhuman primates, CAR-T cells engineered with human NKG2D ligand suppressed senescence markers and SASP factors, demonstrating proof-of-concept that this immunotherapy approach can target senescent cells in primates[29]. Vaccines targeting senescence-associated antigens represent another innovative approach, with vaccination against GPNMB-expressing cells—enriched in senescent cell populations—demonstrating efficacy in extending lifespan in accelerated-aging mouse models[29]. These diverse senolytic mechanisms suggest rich opportunity for optimization and combination therapies.
Despite encouraging early results, substantial uncertainties cloud senolytics' path to widespread clinical application[7][11][26][29]. Most fundamentally, only nine published clinical trials of senolytics exist to date, with just two including control groups, severely limiting evidence quality[7]. The clinical trials completed represent feasibility and safety studies rather than definitive efficacy investigations[7]. While initial findings suggest possible biological efficacy through senescent cell clearance, whether this translates to clinically meaningful improvements in human healthspan or lifespan remains unproven[7][29].
A critical challenge involves identifying which aging individuals have sufficiently high senescent cell burden to benefit from senolytic therapy[7][11][26]. Not all older adults develop pathologically elevated senescent cell accumulation to equivalent degrees, and current biomarkers for quantifying senescent cell burden remain imperfect[7][11][26]. The research community has emphasized the need for personalized approaches that identify individuals with high senescent cell burden who would most likely respond to senolytic intervention[7][26][29]. Some investigators advocate for intermittent "hit-and-run" administration strategies—delivering short pulses of senolytics rather than continuous therapy—based on observations that senescent cells require time to accumulate and that intermittent approaches may prove more tolerable[8][11][26][29].
Additionally, legitimate concerns exist that eliminating senescent cells could interfere with beneficial senescence functions in specific contexts[11][26][29]. Senescent cells release factors promoting tissue regeneration and wound healing, and inappropriately eliminating senescence could impair these regenerative processes[11][26][29]. One thoughtful researcher cautioned that "senolytics are going to kill senescent cells and we believe that some of those senescence functions could be beneficial" and emphasized that "we need to be extremely careful in future translational and clinical studies because we're still in the very early stages"[11]. This nuanced perspective acknowledges that cellular senescence evolved as a stress response mechanism with context-dependent consequences—sometimes protective and sometimes pathogenic[11][26].
While rapamycin, metformin, NAD+ precursors, and senolytics employ distinct primary mechanisms, substantial pathway overlap suggests complementary or potentially synergistic interactions[1][31][33][44][45]. Rapamycin directly inhibits mTORC1 signaling, which integrates nutrient availability and growth signals[1]. Metformin activates AMPK, effectively creating an opposing signal of energy scarcity that opposes mTORC1 activity[5][25]. NAD+ precursors restore capacity for sirtuins and poly-ADP-ribose polymerases to execute DNA repair and stress responses downstream of but not directly modulating mTOR[6]. Senolytics operate at an orthogonal level, targeting the consequences of cellular stress—senescent cell accumulation—rather than primary signaling pathways[8][26][29].
The overlap between these mechanisms suggests that combination therapies might achieve superior outcomes compared to monotherapy[1][31][44][45][47]. Notably, a recent mouse study demonstrated that combining rapamycin with trametinib—a MEK inhibitor that targets a parallel signaling pathway—extended lifespan by approximately thirty percent, substantially exceeding the roughly fifteen to twenty percent extension achieved by either drug alone[44][47]. This additive lifespan extension occurred despite both drugs targeting the insulin-IGF-mTORC1-Ras network, suggesting that targeting multiple nodes within this pathway network amplifies benefits[44][47].
The stage of human clinical evidence development differs markedly among these four intervention classes, with implications for clinical translation timelines[1][31][33][38]. Rapamycin possesses the most robust human safety data through decades of immunosuppressive use in transplant recipients and epilepsy patients[1]. The PEARL trial represents the most extensive investigation of an established geroprotective drug in healthy aging individuals, providing definitive evidence of tolerability and some functional benefits over one year[9][31]. However, even rapamycin lacks long-term randomized controlled data demonstrating that it extends human lifespan or definitively prevents age-related diseases[1].
Metformin similarly benefits from extensive prior clinical use in diabetic populations and the ongoing TAME trial will provide the most definitive evidence regarding its anti-aging potential in non-diabetic aging adults[5][28]. However, emerging uncertainty about metformin's benefits in non-diabetic populations tempers enthusiasm for its universal anti-aging application[13]. The mechanistic basis for discrepancies between observational benefits in diabetics and disappointing results in some non-diabetic populations remains incompletely understood[13].
NAD+ precursors including NR and NMN have accumulated the most extensive collection of short-term safety data from multiple small clinical trials demonstrating excellent tolerability[6][19][38]. The ongoing stable isotope tracer study will provide critical mechanistic understanding of how NAD+ precursor metabolism changes with aging[3]. However, concerning long-term safety data remain absent, and published trials have not demonstrated robust clinical benefits sufficient to support routine anti-aging use[6][19][33][38]. The effects remain predominantly in the healthspan category—modest functional improvements—rather than lifespan extension[19][33].
Senolytics currently occupy the earliest stage of human clinical translation, with only nine published trials and just two randomized controlled investigations[7]. However, these early trials have demonstrated remarkable biological activity—actual clearance of senescent cells from human tissues—combined with acceptable tolerability[7][11][26]. The preliminary evidence for functional improvement in idiopathic pulmonary fibrosis represents the strongest proof-of-concept that senolytic therapy can benefit human health[11][26].
Each intervention carries distinct safety considerations that must factor into risk-benefit calculations for healthy aging individuals[1][4][9][40]. Rapamycin's immunosuppressive effects, even at low doses, raise legitimate concerns about infection risk, impaired wound healing, and potential for chronic administration to compromise immune function in ways that might only become apparent with prolonged follow-up[1][4][40]. The case of entrepreneur Bryan Johnson discontinuing rapamycin due to infection susceptibility and other side effects exemplifies real-world tolerability challenges[40]. Chronic metabolic effects including glucose intolerance and dyslipidemia add additional concerns for populations with metabolic risk factors[1][40].
Metformin demonstrates an exceptional safety record accumulated over six decades of use, with the most common adverse effect being gastrointestinal disturbance typically managed through dose titration and formulation adjustment[5][25]. Rare but serious concerns include lactic acidosis in patients with renal impairment and potential vitamin B12 deficiency with long-term use requiring monitoring[5][25]. Overall, metformin's tolerability profile exceeds that of rapamycin substantially[5][25].
NAD+ precursors including NR and NMN have demonstrated outstanding short-term safety with no serious adverse events reported in published human trials[6][19][38]. The minor side effects reported—primarily gastrointestinal symptoms, occasional flushing, and rare rashes—generally resolve spontaneously[6][19][38]. However, the absence of long-term safety data remains a significant gap, particularly regarding potential interactions with age-related diseases, polypharmacy, or subtle effects emerging only after years of continuous supplementation[38][41].
Senolytics including dasatinib and quercetin have generated acceptable tolerability profiles in early trials with non-serious adverse events predominantly consisting of known dasatinib-related effects including fatigue, nausea, and headache[7][11][42]. No serious adverse events have occurred in completed senolytic trials to date[7][42]. However, the limited number of trials and short treatment durations mean that rare adverse effects might not yet be apparent[7][29].
A fundamental challenge in translating anti-aging interventions to human trials involves identifying appropriate outcome measures that correlate with human lifespan and healthspan within practically achievable trial durations[1][33][43][56][59]. Human lifespan spans decades, rendering direct lifespan-focused trials impractical from both financial and temporal perspectives[1][33][59]. Instead, the field has increasingly relied on biomarkers purporting to quantify biological aging independent of chronological age, allowing researchers to assess whether interventions modify fundamental aging processes[43][50][59].
Multiple categories of biomarkers have emerged as potential measures of biological aging, including epigenetic clocks based on DNA methylation patterns, functional measures such as gait speed and grip strength, inflammatory biomarkers including C-reactive protein and interleukin-6, and molecular biomarkers including growth differentiation factor-15 and insulin-like growth factor-1[43][50][59]. An expert consensus established through the Delphi method identified fourteen biomarkers reaching substantial consensus for use in aging intervention studies, spanning physiological, inflammatory, functional, and epigenetic domains[43].
Epigenetic clocks represent perhaps the most scientifically sophisticated aging biomarkers developed to date, using patterns of DNA methylation at specific cytosine positions across the genome to predict biological age independent of chronological age[50][53]. First-generation clocks like the Horvath clock and Hannum clock predict chronological age with average errors as low as two to three years, demonstrating that DNA methylation patterns exhibit systematic correlation with aging[50][53]. Newer clocks including GrimAge and DunedinPACE incorporate additional refinements to predict mortality and aging rate respectively[50][53].
However, substantial controversy has emerged regarding whether epigenetic clock changes necessarily reflect anti-aging benefits or might sometimes reflect suppression of beneficial aging-associated responses[53]. A 2025 perspective published in Aging articulated this concern, noting that DNA methylation changes accompanying aging fall into at least two categories: Type 1 changes reflecting programmed biological responses that may cause damage, and Type 2 changes reflecting activation of repair mechanisms to oppose aging[53]. An intervention that "sets back" the methylation clock by suppressing Type 2 repair responses might reduce epigenetic age while actually impairing healthspan—a profound paradox for clock-based biomarker interpretation[53].
The absence of standardized biomarker selection and measurement protocols across anti-aging trials substantially impedes comparison of intervention efficacy and prevents meta-analytic synthesis of evidence[43][59]. Different trials employ different biomarkers, use different analytical platforms, and report results in formats that resist direct comparison[43][59]. This heterogeneity means that even when multiple trials investigate the same intervention, pooling results for comprehensive analysis becomes problematic[43][59].
Professional efforts to standardize biomarker selection have accelerated recently, with the Biomarkers of Aging Consortium sponsoring international initiatives to establish consensus on measurement standards and validation criteria[46][59]. The consortium's 2025 Biomarkers of Aging Conference at Harvard Medical School convened leading researchers to address standardization, while the consortium's open-source library provides researchers access to large, high-quality omics and health datasets for biomarker validation[46]. The Biomarkers of Aging Challenge stimulates innovation in developing novel biomarkers with enhanced predictive capacity for chronological age, mortality, and multi-morbidity[46].
Despite these coordination efforts, fundamental questions persist regarding which biomarkers should constitute primary endpoints in aging trials[43][59]. Using lifespan and healthspan as ultimate endpoints remains impractical for human trials, yet selecting surrogate endpoints requires establishing that changes in those surrogates predict clinical benefits—a validation threshold that current aging biomarkers have not yet achieved[43][59]. The FDA's regulatory framework recognizes "validated," "likely," and "candidate" surrogate endpoints based on the strength of evidence predicting clinical outcomes[59]. To date, no aging biomarkers have achieved full FDA validation as surrogate endpoints; most remain at the candidate level[59].
The anti-aging intervention clinical trial landscape has expanded dramatically, with dozens of ongoing and planned investigations testing diverse compounds across multiple research centers[31][33][45][57]. The PEARL trial for rapamycin represents the most extensive healthy aging study completed, with results influencing design of subsequent trials[31]. The TAME trial for metformin, enrolling three thousand participants, represents the most ambitious prospective human aging trial to date, with potential to fundamentally reshape whether metformin receives approval as an anti-aging therapeutic[28][33]. Multiple NR and NMN trials are underway investigating cardiovascular outcomes, cognitive function, and metabolic effects across diverse age groups[6][27].
For senolytics, the ongoing pipeline includes trials in secondary progressive multiple sclerosis, Alzheimer's disease risk (the STAMINA trial), idiopathic pulmonary fibrosis, diabetic kidney disease, and glioma with residual disease[10][14][39]. The Everolimus Aging Study (EVERLAST) will investigate another mTOR inhibitor in aging, while trials examining tirzepatide—a dual GLP-1 and GIP receptor agonist—to slow biological aging highlight emerging interest in repositioning metabolic drugs as gerotherapeutics[45].
One of the most important paradigm shifts in anti-aging research involves recognition that combination therapies targeting multiple aging pathways may outperform single interventions[1][31][44][45][47][57]. The finding that rapamycin plus acarbose produced greater lifespan extension than either alone, reaching 36.6% median lifespan extension in mice, fundamentally reframes how researchers should approach intervention design[31][57]. This suggests that optimal human anti-aging therapy may involve coordinated multi-drug regimens rather than monotherapy[31][45][57].
The comparative success of GLP-1 receptor agonists combined with metformin versus monotherapy exemplifies this principle in clinically approved medications[45][48]. GLP-1 agonists, originally developed for type 2 diabetes, have emerged as potentially the first true longevity medications with effects across multiple aging pathways and strong evidence for reducing all-cause mortality[45][48]. The combination of GLP-1 agonists with SGLT2 inhibitors and metformin achieves superior outcomes regarding mortality, cardiovascular complications, and kidney disease progression compared to any single agent[13][45][48].
Several research groups have proposed combining senolytic therapy with NAD+ precursor supplementation based on mechanistic logic that NAD+ elevation might sustain senescent cells through enhanced bioenergetic capacity, while simultaneous senolytic treatment would eliminate those cells[41][44]. Products combining these approaches are beginning to appear in the marketplace, though definitive clinical trial evidence for the benefit of these combinations remains limited[41].
A fundamental ethical tension underlies therapeutic development for healthy aging: how aggressively should pharmaceutical interventions be pursued in otherwise healthy individuals when long-term benefits remain unproven and risks—even if quantitatively small—are real?[1][4][40]. Unlike treatments for established diseases where efficacy-risk calculations favor intervention despite adverse effects, aging interventions in healthy people require extraordinarily compelling evidence of benefit to justify exposure to pharmaceutical risks[1][40]. The higher threshold reflects that healthy individuals have no disease to treat, making any adverse effects pure harm rather than acceptable trade-offs against disease burden[1][40].
Current regulatory frameworks lack clear pathways for approving medications specifically as "anti-aging" interventions[1][33][59]. Most candidate gerotherapeutics would require demonstration of efficacy against specific age-related diseases (cardiovascular disease, cognitive decline, frailty, etc.) rather than aging per se[1][33][59]. The TAME trial's innovative endpoint structure—using time to first occurrence of any aging-related morbidity—represents an attempt to design trials around aging biology rather than individual diseases, potentially creating novel regulatory pathways[28][33].
Anti-aging interventions, particularly early-stage therapeutics and biomarker testing, risk exacerbating existing health disparities by remaining accessible only to affluent individuals[31]. NAD+ precursor supplementation, biomarker testing, clinical trial participation, and off-label prescribing of drugs like rapamycin are currently available primarily to those with substantial financial resources and medical sophistication[31][40]. As these interventions advance, ensuring equitable access will require deliberate policy interventions including pricing controls, insurance coverage decisions, and ensuring research diversity[31].
The case of Bryan Johnson—a millionaire able to afford extensive biohacking protocols including rapamycin, NAD+ precursors, and comprehensive biomarker monitoring—exemplifies the current inequality in anti-aging access[40]. Most aging adults lack such resources and must rely on whatever interventions become accessible through healthcare systems. Without intentional efforts to ensure equity, anti-aging medicine risks becoming another dimension of healthcare inequality where the wealthy receive cutting-edge interventions while others lack access to even established preventive approaches[40][48].
The past decade has witnessed remarkable scientific progress in identifying and clinically translating anti-aging interventions. Rapamycin, metformin, NAD+ precursors, and senolytics represent the current frontiers of gerotherapeutics, each demonstrating compelling preclinical evidence and varying degrees of human clinical validation. However, the translation from animal models to robust human clinical benefits remains incomplete, and substantial scientific uncertainties persist regarding which interventions offer the greatest promise for extending healthy human lifespan[1][31][33][43][59].
Rapamycin stands as the most thoroughly validated single anti-aging compound in mammalian lifespan studies, with decades of clinical experience in other therapeutic contexts and emerging evidence for immune function improvement in aging populations[1][4][9][31][51]. However, concerns regarding long-term immunosuppression, metabolic side effects, and the gap between dramatic mouse lifespan extension and modest human functional benefits temper enthusiasm for universal application[1][4][40]. Future rapamycin research should focus on optimizing dosing regimens, identifying patient subpopulations most likely to benefit, and determining whether low-dose intermittent approaches can achieve lifespan extension comparable to continuous regimens in mouse models[1][9].
Metformin's extensive epidemiological support for reducing mortality in diabetic patients must be reconciled with emerging uncertainty about anti-aging benefits in non-diabetic populations[13][28]. The TAME trial represents the definitive human investigation that will clarify whether metformin extends healthspan and lifespan in healthy aging adults[28]. Until TAME results become available, metformin's anti-aging recommendation must remain contingent and potentially beneficial primarily for individuals with metabolic risk factors rather than universal anti-aging application[13].
NAD+ precursors, particularly NMN and NR, occupy an unusual position with excellent short-term safety records and modest functional improvements but concerning absence of long-term safety data and absence of demonstrated lifespan extension in humans[6][19][33][38]. The mechanistic metabolic investigation now underway will provide critical guidance regarding optimal dosing and bioavailability across age groups[3]. However, before these compounds become routine anti-aging supplements for healthy populations, longer-term randomized controlled trials demonstrating clinical benefits and establishing definitive safety profiles will be essential[6][38].
Senolytics represent perhaps the most exciting frontier in anti-aging medicine, with the unique advantage of demonstrating actual biological activity—clearance of senescent cells from human tissues—in early clinical trials[7][11][26]. The proof-of-concept demonstration that senolytic therapy improves physical function in idiopathic pulmonary fibrosis patients provides the strongest evidence to date that targeting a fundamental aging mechanism can benefit humans[11][26]. However, the field remains early in clinical translation, and defining which aging individuals have sufficiently elevated senescent cell burden to benefit from senolytics represents a critical near-term research priority[7][26][29].
Several strategic research directions warrant prioritization to accelerate translation of anti-aging interventions to clinical benefit. First, the field must establish standardized biomarkers of aging that reliably predict human lifespan and healthspan across diverse populations, with particular attention to distinguishing biomarker changes reflecting benefits from those reflecting harm[43][50][53][59]. The current heterogeneity in biomarker selection impedes meta-analysis and comparative evaluation of interventions[43][59].
Second, mechanistic investigations elucidating why effects documented in mouse models sometimes fail to manifest in humans—or manifest only weakly—should accelerate[1][33][43][59]. The gap between dramatic lifespan extension in mice and modest functional improvements in rapamycin-treated humans suggests fundamental differences in mouse versus human aging that deserve better characterization[1][9].
Third, combination therapy approaches deserve systematic investigation based on evidence that multi-pathway targeting outperforms single interventions[31][44][45][47]. Future trials should explicitly test whether combining rapamycin with metformin, or combining senolytics with NAD+ precursors, produces superior outcomes compared to monotherapy[44][47].
Fourth, patient stratification strategies identifying individuals most likely to benefit from specific interventions should be developed to enable precision gerontology approaches[7][25][26][29]. Not all older adults benefit equally from anti-aging interventions, and genetic, metabolic, and inflammatory profiles likely predict who will derive maximum benefit from specific therapies[25][26][29].
Finally, long-term safety monitoring systems must be established for anti-aging interventions currently used off-label, particularly rapamycin, to capture information on potential adverse effects emerging only after years of exposure[1][40][51]. The existing pharmacovigilance systems focus on approved indications and may miss safety signals relevant to novel anti-aging applications[1].
In conclusion, the anti-aging interventions currently in clinical trials represent genuine scientific progress toward extending healthy human lifespan and preventing age-related disease. However, these interventions remain at varying stages of human clinical validation, with some showing greater promise than others. Rapamycin, metformin, NAD+ precursors, and senolytics each offer distinct mechanistic approaches, and emerging evidence suggests that combinations targeting multiple aging pathways may prove superior to monotherapy. The coming years will be critical as major trials like TAME complete enrollment and generate results that could fundamentally reshape clinical perspectives on aging. Until then, healthy adults should base anti-aging decisions on established lifestyle interventions—regular exercise, adequate sleep, healthy diet, cognitive engagement, and social connectivity—while remaining appropriately skeptical of unproven pharmacological claims, however scientifically compelling the underlying rationale may appear[48][49]. The promise of genuine geroprotective medications remains real, but realizing that promise will require sustained scientific effort, rigorous clinical investigation, and commitment to evidence-based translation from bench to bedside.
The landscape of geroscience has shifted from preclinical speculation to rigorous human clinical validation. As of late 2024 and through 2025, the field has witnessed pivotal data readouts concerning four major classes of geroprotectors: mTOR inhibitors (rapamycin), biguanides (metformin), NAD+ precursors, and senolytics.
Key findings include:
The hypothesis that aging is a malleable biological process rather than an inevitable decline is now being tested in human subjects. The transition from model organisms (yeast, worms, mice) to humans introduces significant complexity, particularly regarding dosage, safety profiles in non-diseased populations, and the selection of biomarkers. Current clinical trials focus less on "lifespan" (which takes decades to measure) and more on "healthspan" metrics, including epigenetic clocks, frailty indices, cognitive function, and mitochondrial competency.
This report synthesizes data from 2024 and 2025 to evaluate the efficacy and safety of the most prominent anti-aging interventions.
Rapamycin (Sirolimus), an FDA-approved immunosuppressant, acts by inhibiting the mechanistic target of rapamycin (mTOR), specifically the mTORC1 complex, which regulates cell growth and autophagy. It is currently considered the "gold standard" for pharmacological lifespan extension in animal models.
The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial, a randomized, double-blind, placebo-controlled study, released its findings in April 2025. This study aimed to assess the safety and efficacy of intermittent (weekly) low-dose rapamycin in healthy older adults [cite: 1, 2].
A comprehensive meta-analysis published in Aging Cell (June 2025) analyzed 167 studies across eight vertebrate species to compare the lifespan-extending effects of Rapamycin, Metformin, and Dietary Restriction (DR) [cite: 5, 6].
The PEARL trial suggests that rapamycin's utility in humans may lie in preserving functional capacity (muscle mass) rather than simply reducing fat. The specific targeting of mTORC1 appears to induce autophagy without the deleterious side effects associated with continuous high-dose inhibition (which affects mTORC2 and insulin sensitivity) [cite: 1]. Future trials are expected to explore higher doses and longer durations to establish definitive longevity benefits [cite: 2].
Metformin, a first-line treatment for Type 2 diabetes, acts primarily by activating AMPK and inhibiting Complex I of the mitochondrial electron transport chain. It has been hypothesized to act as a "caloric restriction mimetic."
The Targeting Aging with Metformin (TAME) trial, led by Dr. Nir Barzilai, was designed to test whether metformin can delay the onset of a composite of age-related diseases (cancer, cardiovascular disease, dementia) in non-diabetics.
Despite the delays in TAME, a groundbreaking study published in Cell (2024) provided robust evidence for metformin's neuroprotective effects in primates [cite: 9, 10, 11].
While the 2025 meta-analysis suggests rapamycin is superior for lifespan extension [cite: 6, 14], metformin appears to have a distinct and potent role in specific organ protection, particularly the brain and liver. The divergence suggests that rapamycin may be a "generalist" longevity drug, while metformin may be a "specialist" for metabolic and neuro-cognitive preservation [cite: 15]. Furthermore, metformin's safety profile is established over 60 years of human use, whereas rapamycin's off-label safety is only recently being validated [cite: 14].
Nicotinamide Adenine Dinucleotide (NAD+) declines with age, compromising mitochondrial function and DNA repair. Supplementation with precursors like Nicotinamide Riboside (NR) and Nicotinamide Mononucleotide (NMN) aims to restore these levels.
A critical human trial published in Nature Metabolism (2025) directly compared the pharmacokinetics of NR, NMN, and Nicotinamide (Nam) in healthy adults [cite: 16].
A 2025 clinical trial conducted by Chiba University provided the first evidence of NR's efficacy in Werner Syndrome, a genetic premature aging disorder [cite: 17, 18].
A 2024 randomized controlled trial evaluated NMN (250 mg/day) in older adults over 12 weeks [cite: 21].
Senolytics are compounds designed to induce apoptosis specifically in senescent ("zombie") cells that accumulate with age and secrete inflammatory factors (SASP). The most studied combination is Dasatinib (a tyrosine kinase inhibitor) and Quercetin (a flavonoid).
A longitudinal study examining the effects of Dasatinib and Quercetin (D+Q) revealed a complex biological response [cite: 25, 26].
Beyond the four primary categories, two interventions have made significant strides in 2024/2025.
Urolithin A is a postbiotic metabolite that activates mitophagy (recycling of defective mitochondria).
Partial epigenetic reprogramming involves using Yamanaka factors (OSK) to reset the epigenome of cells to a youthful state without inducing pluripotency (which risks cancer).
| Intervention | Mechanism | Key 2024/2025 Human Finding | Primary Benefit Observed | Status |
|---|---|---|---|---|
| Rapamycin | mTORC1 Inhibition | PEARL Trial: Safe in healthy adults; increased lean mass in women [cite: 2]. | Muscle preservation, pain reduction. | Phase 2/3 (Off-label studies) |
| Metformin | AMPK Activation | Primate Study: 6-year brain age reduction [cite: 10]. Vertebrate meta-analysis: No lifespan extension [cite: 6]. | Neuroprotection, metabolic health. | TAME pending; widely used off-label. |
| NAD+ (NR/NMN) | NAD+ Restoration | NMN/NR double blood NAD+ via gut conversion [cite: 16]. NR treats Werner syndrome symptoms [cite: 17]. | Vascular health, walking speed, sleep. | Various Phase 2 trials completed. |
| Senolytics | Senescent Cell Clearance | D+Q increases epigenetic age temporarily; Fisetin mitigates this [cite: 25]. | Clearance of senescent cells (proven), cognitive hints. | Early Phase 1/2; safety established. |
| Urolithin A | Mitophagy Induction | MitoImmune Trial: Rejuvenates T-cells and restores immune function [cite: 34]. | Immune health, muscle strength/endurance. | Multiple successful trials; commercialized. |
The years 2024 and 2025 mark a maturation point for anti-aging clinical trials. Rapamycin has solidified its position as the most robust lifespan extender in vertebrates, with human data now supporting its safety and ability to preserve muscle mass. Metformin, while struggling to prove lifespan extension in non-diabetics, has demonstrated profound neuroprotective capabilities in primates, suggesting it may be an essential "healthspan" tool for cognitive aging.
NAD+ precursors have moved beyond bioavailability debates, with clear evidence that both NMN and NR are effective at raising NAD+ through microbiome-dependent pathways, translating to tangible vascular and functional benefits. Senolytics remain promising but complex, requiring careful management of the inflammatory response associated with cell clearance.
Finally, the entry of epigenetic reprogramming into FDA-cleared human trials in 2026 represents the transition of longevity science from slowing decline to actively reversing cellular age. The most promising intervention appears to depend on the specific outcome desired: Rapamycin for general longevity and frailty prevention, Metformin for cognitive/metabolic protection, Urolithin A for mitochondrial/immune vigor, and NAD+ precursors for vascular/energy support.
Sources:
Want this comparison for your own question? Run a blind battle between deep research AIs or see the deep research API leaderboard from all community votes.